Literature DB >> 3757408

Computerized comparison of six adverse drug reaction assessment procedures.

J C Pere, B Begaud, F Haramburu, H Albin.   

Abstract

Several standardized assessment procedures are currently used in the evaluation of adverse drug reactions (ADRs). Disagreement in rating ADRs can result from between-raters variability and between-methods differences in weighting the evidence. We eliminated between-raters variability by computer simulation of 1134 ADRs (including all the possible combinations of criteria currently used) and by automatic rating using different algorithms adapted from six published methods. Percentage agreement (Po) and weighted kappa test (kappa w) between pairs of methods are always better than with randomized scores, but the strength of agreement is only moderate (0.26 less than Po less than 0.59; 0.14 less than kappa w less than 0.51). The weightings of criteria are evaluated in terms of sensitivity, specificity, and predictive values. Criteria are neither sensitive (0.41 less than Se less than 0.70) nor specific (0.18 less than Sp less than 0.63) and have poor predictive values. Disagreements on weightings are considerable for three major criteria: timing of event, dechallenge, and alternative etiologic candidates. We discuss some ways of improving reliability of ADR diagnosis.

Entities:  

Mesh:

Year:  1986        PMID: 3757408     DOI: 10.1038/clpt.1986.206

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Agreement of expert judgment in causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Bernard Bégaud; Ghada Miremont-Salamé; Annie Fourrier-Réglat; Nicholas Moore; Mathieu Molimard; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2005-04-13       Impact factor: 2.953

2.  Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs?

Authors:  Ana F Macedo; Francisco B Marques; Carlos F Ribeiro
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Methods for causality assessment of adverse drug reactions: a systematic review.

Authors:  Taofikat B Agbabiaka; Jelena Savović; Edzard Ernst
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Ghada Miremont-Salamé; Françoise Haramburu; Mathieu Molimard; Nicholas Moore; Annie Fourrier-Réglat; Bernard Bégaud
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

5.  Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference.

Authors:  Hélène Théophile; Manon André; Ghada Miremont-Salamé; Yannick Arimone; Bernard Bégaud
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Causal or casual? The role of causality assessment in pharmacovigilance.

Authors:  R H Meyboom; Y A Hekster; A C Egberts; F W Gribnau; I R Edwards
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

Review 7.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

8.  The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.

Authors:  Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

9.  A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions.

Authors:  Mahesh N Belhekar; Santosh R Taur; Renuka P Munshi
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.